The line will feature approximately 10 instruments, six of which are modifications to current product offerings, and five completely redesigned instruments; all of which have FDA clearance.

Solos’ focus is to strengthen its domestic market share in the industry through the implementation of several strategies and the addition of new product lines throughout 2011.

In addition, Solos will continue building product awareness and is currently in the process of updating its corporate website.

Finally, the company plans to expand its research and development efforts to develop new instrumentation to better assist physicians.